Search clinical trials for: Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine

Total 68 results

National Cancer Institute (NCI)

Active, not recruiting

Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial

Human Papillomavirus-Related Cervical Carcinoma

Costa Rica
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)

Prevention | Papillomavirus Infection | Healthy Adult Female Participants | Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
Merck Sharp & Dohme LLC

Completed

V501 Efficacy Study in Women Aged 18 to 26 (V501-027)

HPV Infections
Merck Sharp & Dohme LLC

Suspended

Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)

HPV Infections
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | Human Papillomavirus Infection | Genital Warts
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)

Papillomavirus Infections
Merck Sharp & Dohme LLC

Completed

An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035)

HPV Infections
PATH
National Institute of Hygiene and Epidemiology, Vietnam

Completed

Immunogenicity and Reactogenicity of Alternative Schedules of Gardasil

Dose Schedule Study

Vietnam
Merck Sharp & Dohme LLC

Completed

Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)

HPV Infections
Merck Sharp & Dohme LLC

Completed

Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED)

Neoplasms, Glandular and Epithelial | Whooping Cough | Tetanus | Diphtheria | Poliomyelitis
Merck Sharp & Dohme LLC

Completed

V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)

HPV Infections
AIDS Malignancy Consortium
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; University of Arkansas and other collaborators

Completed

Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males

Precancerous Condition | Anal Cancer | Penile Cancer | Nonneoplastic Condition

United States, Puerto Rico
Merck Sharp & Dohme LLC

Completed

GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)

Papillomavirus Infections
Merck Sharp & Dohme LLC

Completed

An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)

Papillomavirus Infections
Shanghai Bovax Biotechnology Co., Ltd.

Terminated

A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females

Cervical Cancer | CIN1 | CIN2 | CIN3 | Genital Wart | AIS | Vain I | Vain III | Vin I | Vin II | Vin III | VAIN - Vaginal Intraepithelial Neoplasia 2

China
AIDS Malignancy Consortium
National Cancer Institute (NCI); The Emmes Company, LLC

Completed

Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection

Infection | Precancerous Condition

United States
Merck Sharp & Dohme LLC

Completed

An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)

Condylomata Acuminata
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children

HIV Infections | Sexually Transmitted Diseases

United States, Puerto Rico
Merck Sharp & Dohme LLC

Completed

Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | Human Papillomavirus Infection | Genital Warts
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®

Dengue Fever | Dengue Hemorrhagic Fever | Human Papillomavirus Disease

Malaysia
Merck Sharp & Dohme LLC

Completed

Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)

Cervical Cancer | Genital Warts
University of Alabama at Birmingham
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Completed

Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors

Cancer Survivor | Prevention of Human Papillomavirus Infection

United States
Universidad Nacional Autonoma de Mexico
Merck Sharp & Dohme LLC; Secretaria de Salud, Mexico

Unknown

Two-dose Schedule of Quadrivalent HPV Recombinant Vaccine in 11-year-old Boys in Mexico City

Human Papilloma Virus

Mexico
Beijing Health Guard Biotechnology, Inc

Active, not recruiting

A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine

Human Papillomavirus Infection

China
Beijing Health Guard Biotechnology, Inc
National Institutes for Food and Drug Control, China; Jiangsu Province Centers... and other collaborators

Completed

A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine

Human Papillomavirus Infection

China
Merck Sharp & Dohme LLC

Completed

Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED) (FUTURE)

Cervical Cancer | Genital Warts
Beijing Health Guard Biotechnology, Inc
National Institutes for Food and Drug Control, China; Jiangsu Province Centers... and other collaborators

Completed

A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine

Human Papilloma Virus Infection

China
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)

Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ

China
Merck Sharp & Dohme LLC

Completed

Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)

Cervical Cancer | Genital Warts
University of Milan

Unknown

Long Term Immunogenicity of Quadrivalent Human Papillomavirus Vaccine (Gardasil®)in HIV-infected Adolescents and Young Adults

HIV | HPV

Italy
Merck Sharp & Dohme LLC

Active, not recruiting

Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015) (FUTURE II)

Cervical Cancer | Genital Warts
GlaxoSmithKline

Completed

Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females

Infections, Papillomavirus | Papillomavirus Vaccines

Thailand, Estonia, India, Brazil
Beijing Health Guard Biotechnology, Inc
National Institutes for Food and Drug Control, China; Yunnan Center for Disease... and other collaborators

Active, not recruiting

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Human Papillomavirus Infection

China
AIDS Malignancy Consortium
National Cancer Institute (NCI); The Emmes Company, LLC

Completed

Vaccine Therapy in Preventing HPV in HIV-Positive Women in India

Cervical Cancer | Precancerous Condition | Nonneoplastic Condition

India
Weill Medical College of Cornell University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; University of Sao Paulo and other collaborators

Active, not recruiting

Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV

HPV Infection | HIV-1-infection | HPV Positive Oropharyngeal Squamous Cell Carcinoma

Brazil, Mexico, Puerto Rico
National Cancer Institute (NCI)
Bill and Melinda Gates Foundation

Enrolling by invitation

Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study (ESCUDDO)

Human Papillomavirus Infection | Human Papillomavirus-Related Cervical Carcinoma

Costa Rica
Shanghai Bovax Biotechnology Co., Ltd.

Recruiting

Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | CIN1 | CIN2 | CIN3 | VaIN1 | VaIN2 | VaIN3 | Genital Wart | VIN 1 | VIN 2 | VIN 3 | AIS

China
National Cancer Institute (NCI)

Active, not recruiting

Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial (PRISMA)

Cervical Carcinoma | Human Papillomavirus Infection

Costa Rica
Shanghai Zerun Biotechnology Co.,Ltd
Yuxi Zerun Biotechnology Co., Ltd.

Completed

Lot Consistency Clinical Trial of Bivalent HPV Vaccine in 9 to 30 Years Old Healthy Females

HPV Infection

China
Beijing Health Guard Biotechnology, Inc
University of Muhammadiyah Malang Hospital; Dr. M Djamil Hospital, Padang

Active, not recruiting

A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine

Human Papillomavirus Infection

Indonesia
Shanghai Bovax Biotechnology Co., Ltd.
Chongqing Bovax Biopharmaceutical Co., Ltd.

Completed

Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | CIN1 | CIN2 | CIN3 | VaIN1 | VaIN2 | VaIN3 | Genital Wart | VIN 1 | VIN 2 | VIN 3 | AIS | HPV Infections

China
University Hospital, Ghent

Completed

Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®) (HPVXneutra001)

Infection With Human Papillomavirus

Belgium
Medstar Health Research Institute
Merck Sharp & Dohme LLC

Completed

Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?

Cervical Cancer | Warts | Hpv

United States
Kenya Medical Research Institute
University of Washington

Not yet recruiting

Effectiveness and B-memory Cell Response to QHPV Vaccine 9-years Post-vaccination Among HIV-infected Boys and Girls

HPV-Related Carcinoma
University of Washington
Merck Sharp & Dohme LLC

Completed

Effectiveness of the Q-HPV Vaccine 9-years Post Vaccination Among HIV Positive Adolescents

HPV Infection | HPV Vaccination

Kenya
Washington University School of Medicine

Completed

The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata

HIV Infections | HIV Positive | Anal Condylomata | Anal Warts

United States
Kenya Medical Research Institute
Merck Sharp & Dohme LLC; University of Washington

Completed

Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys

HPV Infection | HPV Vaccine | HIV-1-infection

Kenya
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®

Dengue Fever | Dengue Hemorrhagic Fever | Human Papillomavirus Disease

Mexico
Xiamen University
Xiamen Innovax Biotech Co., Ltd; Center for Disease Control and Prevention,...

Not yet recruiting

Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls

Cervical Cancer | Cervical Intraepithelial Neoplasia | Persistent Infection

China
Zagazig University

Completed

Gardasil Versus Cervarix in the Treatment of Warts

Verruca Viral

Egypt

Search clinical trials for: Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations